Metabolic Reprogramming of Monocytes in Inflammatory Flares of Inflammatory Bowel Diseases

Inflammatory bowel diseases, Crohn's disease and haemorrhagic rectocolitis, are pathologies that progress in flare-ups, impacting on patients' quality of life and functional or even vital prognosis. These inflammatory diseases require the use of immunosuppressive and immunomodulatory treatments, the side-effects of which can be significant, and the limited number of which sometimes puts patients and practitioners in a therapeutic impasse from which surgery is the only way out. It is therefore important to be able to develop new therapeutic approaches, ideally better tolerated, that can control inflammation during relapses. Monocytes are one of the main players in the inflammatory reaction. In the laboratory, we have developed a strategy for the metabolic reprogramming of these cells based on the use of oxygen microbubbles to modulate the inflammatory response of monocytes.

NCT Number	NCT06944873
Lead Sponsor	University Hospital, Grenoble Collaborators: Institute for Advanced Biosciences (IAB), Grenoble
Conditions	Inflammatory Bowel Disease (IBD)
Enrollment	30 participants
Start Date	2026-07-01
Primary Completion	2028-04-30 (estimated)
Study Completion	2028-07-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-19